TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2270531

Group type: COMPARATOR
Intervention: Intravenous heparin sodium by continuous infusion for 6-10 days
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin calcium, intermittent for 6-10 days
Number of subjects: 271
Study: 6258959

Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate aerosol (1.0‐1.25 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 7
Study: 31924771

Group type: EXPERIMENTAL
Intervention: Gene expression levels in multiple tissues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue-specific associations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Causal pathways for trait-associated variants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Putative associations at loci
Number of subjects: 0
Study: 31036336

Group type: EXPERIMENTAL
Intervention: Restrictive strategy with stepwise selection for cholecystectomy
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Restrictive strategy
Number of subjects: 1067
Study: 27575013

Group type: EXPERIMENTAL
Intervention: Denneroll™ cervical traction
Number of subjects: 72

Group type: COMPARATOR
Intervention: Multimodal program without Denneroll™ cervical traction
Number of subjects: 72
Study: 27007068

Group type: EXPERIMENTAL
Intervention: 60 mg/d etoricoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25081826

Group type: EXPERIMENTAL
Intervention: PAS 400 (400 mg PS & 400 mg PA per day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PAS 200 (200 mg PS & 200 mg PA per day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 22322124

Group type: EXPERIMENTAL
Intervention: Single cleansing with chlorhexidine
Number of subjects: 29760

Group type: EXPERIMENTAL
Intervention: Multiple cleansing with chlorhexidine
Number of subjects: 29760

Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 29760
Study: 19531605

Group type: EXPERIMENTAL
Intervention: Interactive rehabilitation robot (n = 15)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Passive motion device (n = 12)
Number of subjects: 27
Study: 17973637

Group type: EXPERIMENTAL
Intervention: 5-HT(3) antagonist ondansetron given orally
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 22
Study: 15297089

Group type: EXPERIMENTAL
Intervention: High-contrast red tableware (intervention)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-contrast blue tableware (follow-up intervention)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-contrast red and low-contrast blue tableware (follow-up interventions)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Baseline (white tableware)
Number of subjects: 9
Study: 11337927

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of mt‐PA (monteplase) 15,000 IU/kg
Number of subjects: 46

Group type: COMPARATOR
Intervention: No mt‐PA (control group)
Number of subjects: 46
Study: 9447279

Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy for 6 months
Number of subjects: 11
Study: 8941780

Group type: EXPERIMENTAL
Intervention: Ibuprofen effervescent granules 600 mg (Brufen Granules)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ibuprofen tablets 600 mg
Number of subjects: 100
Study: 3115228

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cefazolin and Moxalactam
Number of subjects: 90
Study: 30218062

Group type: EXPERIMENTAL
Intervention: Single oral dose of 200,000 IU vitamin D3
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 27096709

Group type: EXPERIMENTAL
Intervention: Cyclosporine lipogel, 2.0% w/w
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream, 0.05% w/w
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional cyclosporine cream, 2.0% w/w
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo lipogel
Number of subjects: 38
Study: 26292178

Group type: EXPERIMENTAL
Intervention: Individual cognitive stimulation therapy (iCST)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 273
Study: 24228534

Group type: EXPERIMENTAL
Intervention: Immune 1 combined HAART
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo combined HAART
Number of subjects: 228
Study: 21395575

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 18363913

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser 532 nm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser 1064 nm
Number of subjects: 20
Study: 14627758

Group type: EXPERIMENTAL
Intervention: Individualized counseling for diet and exercise over 24 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: No psychiatric diagnosis
Number of subjects: 48
Study: 10934552

Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinine-Fansidar
Number of subjects: 0
Study: 8779651

Group type: EXPERIMENTAL
Intervention: Folic acid fortification in flour
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (current situation without fortification)
Number of subjects: 0
Study: 2095341

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (ES) 1000 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 800 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 81243

Group type: EXPERIMENTAL
Intervention: Intradermal injection of synthetic substance P (10(‐7)‐‐10(‐5) M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral pretreatment with chlorcyclizine (antihistaminic drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local pretreatment with Compound 48/80
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substance P
Number of subjects: 0
Study: 31050685

Group type: EXPERIMENTAL
Intervention: Revised Perceived Stress Scale (PSS-14)
Number of subjects: 367
Study: 27683800

Group type: EXPERIMENTAL
Intervention: Vedolizumab (open-label) every 4 weeks
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Increased dosing to vedolizumab every 4 weeks (from every 8 weeks)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Vedolizumab (every 4 weeks)
Number of subjects: 532
Study: 26372493

Group type: EXPERIMENTAL
Intervention: Pediatric anesthesia procedures
Number of subjects: 486900
Study: 24195823

Group type: EXPERIMENTAL
Intervention: Non-drainage group
Number of subjects: 272

Group type: COMPARATOR
Intervention: Drainage group
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 272
Study: 21346163

Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure (SBP) variability outside a range of 75 to 135 mm Hg intraoperatively and 85 to 145 mm Hg pre- and postoperatively.
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Low-risk patients with SBP variability
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: High-risk patients with SBP variability
Number of subjects: 1512
Study: 19838998

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (133 mg or 200 IUs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (non-supplemented subjects)
Number of subjects: 14
Study: 16685705

Group type: EXPERIMENTAL
Intervention: Tree-type method for estimating baseline hazards and covariate effects with time-dependent covariates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional proportional hazard model
Number of subjects: 0
Study: 14987324

Group type: EXPERIMENTAL
Intervention: Peginterferon plus ribavirin combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline serum interferon-gamma-inducible protein-10 levels greater than 299 pg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline serum interferon-gamma-inducible protein-10 levels lower than 299 pg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased serum interferon-gamma-inducible protein-10 levels at baseline
Number of subjects: 0
Study: 11476461

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice daily) in group 1p (N = 14)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice daily) in group 2p (N = 14)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice daily) in group 3p (N = 11)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional therapy in groups 1c, 2c, and 3c (N = 24)
Number of subjects: 63
Study: 9489812

Group type: EXPERIMENTAL
Intervention: Community based physical therapy (PT) program, at least 4 visits or 3 hours of PT over 6 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Wait list control group (CG)
Number of subjects: 150
Study: 7921207

Group type: EXPERIMENTAL
Intervention: 10 micrograms GHRH(1-29)NH2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 micrograms GHRH(1-29)NH2
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1 microgram GHRH(1-29)NH2
Number of subjects: 10
Study: 3166359

Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg administered orally or intravenously
Number of subjects: 31
Study: 30335527

Group type: EXPERIMENTAL
Intervention: High anger appeal message
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Low anger appeal message
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: High efficacy appeal message
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Low efficacy appeal message
Number of subjects: 551

Group type: COMPARATOR
Intervention: No exposure control group
Number of subjects: 551
Study: 28301825

Group type: EXPERIMENTAL
Intervention: Combined knee brace and foot orthotic
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no knee brace or foot orthotic)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Knee brace
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Foot orthotic
Number of subjects: 35
Study: 26096139

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (single dose, 1000 mg) + low-fat meal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (single dose, 1000 mg) + high-fat meal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg + 5 mg prednisone twice daily) + high-fat meal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg + 5 mg prednisone twice daily) + low-fat meal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modified fasting state
Number of subjects: 60
Study: 23462149

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and physical activity), average duration 4.2 ± 2.0 years
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and physical activity)
Number of subjects: 146
Study: 21304921

Group type: EXPERIMENTAL
Intervention: Delivery of IPTc by Village Health Workers (VHWs)
Number of subjects: 10400

Group type: COMPARATOR
Intervention: Delivery of IPTc through RCH trekking teams
Number of subjects: 10400

Group type: EXPERIMENTAL
Intervention: Delivery of IPTc by VHWs
Number of subjects: 10400

Group type: EXPERIMENTAL
Intervention: IPTc efficacy
Number of subjects: 10400
Study: 19656736

Group type: EXPERIMENTAL
Intervention: Selective ganglionated plexi ablation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anatomic ablation targeting the anatomic areas of ganglionated plexi
Number of subjects: 80
Study: 17299808

Group type: EXPERIMENTAL
Intervention: Intervention (depression care manager offering algorithm‐based care for depression)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 599
Study: 14968327

Group type: EXPERIMENTAL
Intervention: Tacalcitol emulsion (4 micro g/g) once daily
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 11481622

Group type: COMPARATOR
Intervention: Engerix‐B (0, 1, 6 regimen)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Triple antigen vaccine (2-dose regimen: 0, 1)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Triple antigen vaccine (3-dose regimen: 0, 1, 6)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Triple antigen vaccine
Number of subjects: 304
Study: 9570610

Group type: EXPERIMENTAL
Intervention: Meperidine 40 mg (Group A)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Meperidine 40 mg followed by naloxone 0.04 mg (Group B)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Meperidine 40 mg followed by naloxone 0.2 mg (Group C)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Normal saline placebo (Group D)
Number of subjects: 123
Study: 7822064

Group type: EXPERIMENTAL
Intervention: Strength training (ST) for 20 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) for 20 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: No exercise (control group) for 20 weeks
Number of subjects: 26
Study: 3171787

Group type: COMPARATOR
Intervention: Forced expiratory technique alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy with percussion and postural drainage
Number of subjects: 0
Study: 31635976

Group type: EXPERIMENTAL
Intervention: aQIV
Number of subjects: 1778

Group type: COMPARATOR
Intervention: aTIV-1
Number of subjects: 1778

Group type: COMPARATOR
Intervention: aTIV-2
Number of subjects: 1778
Study: 30243130

Group type: EXPERIMENTAL
Intervention: Gabapentin treatment (300 mg/day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 28673350

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mock Laser
Number of subjects: 96
Study: 26133204

Group type: EXPERIMENTAL
Intervention: Kundalini yoga (KY) program for 8 weeks
Number of subjects: 40
Study: 22941671

Group type: EXPERIMENTAL
Intervention: Combined measure of the Functional Independence Measure (FIM) and the Nottingham Extended Activities of Daily Living (NEADL)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 36-item scale
Number of subjects: 188
Study: 21118502

Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g intravenously)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (3 g intravenously)
Number of subjects: 176
Study: 18608041

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40-80 mg/d
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg followed by 75 mg/d
Number of subjects: 54

Group type: COMPARATOR
Intervention: Aspirin 160-325 mg daily (Control)
Number of subjects: 54
Study: 16965522

Group type: EXPERIMENTAL
Intervention: SRP + CHX
Number of subjects: 29

Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 29
Study: 12771471

Group type: EXPERIMENTAL
Intervention: Intramuscular alefacept 15 mg
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 11044791

Group type: EXPERIMENTAL
Intervention: HMG‐CoA reductase inhibitor (pravastatin 10 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No medical treatment (nontreated group)
Number of subjects: 56
Study: 9088649

Group type: EXPERIMENTAL
Intervention: Family size (increase of one sibling)
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Birth order
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Family size and birth order
Number of subjects: 1159
Study: 8259610

Group type: EXPERIMENTAL
Intervention: PRP-D vaccine coadministered with Di-Te-Pol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 21
Study: 3862463

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate only
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate plus cranial irradiation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate plus intermediate dose methotrexate
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall incidence of abnormal scans
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: None of the three methods of CNS prophylaxis
Number of subjects: 93
Study: 30478001

Group type: EXPERIMENTAL
Intervention: Azithromycin oral solution 10 mg/kg per day for 3 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 26503204

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 302
Study: 24493716

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) plus involved-field RT (36 Gy)
Number of subjects: 166

Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) without RT
Number of subjects: 166

Group type: COMPARATOR
Intervention: R-CHOP without RT (per-protocol analysis excluding 11 patients who received unplanned RT)
Number of subjects: 166
Study: 23250593

Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nootropil
Number of subjects: 60
Study: 20164561

Group type: EXPERIMENTAL
Intervention: PBT2 250 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18364392

Group type: EXPERIMENTAL
Intervention: Simple algorithm
Number of subjects: 273

Group type: COMPARATOR
Intervention: Carbohydrate counting (carb count)
Number of subjects: 273
Study: 15467775

Group type: EXPERIMENTAL
Intervention: Orlistat, 120 mg three times daily with hypocaloric diet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (healthy age-matched subjects)
Number of subjects: 36
Study: 14650571

Group type: EXPERIMENTAL
Intervention: Experimental acupuncture treatment (specific acupuncture body points related to menopausal symptoms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison acupuncture treatment (general tonic designed to benefit the flow of Ch'i)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experimental acupuncture treatment and Comparison acupuncture treatment
Number of subjects: 0
Study: 10798650

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine
Number of subjects: 243

Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 243
Study: 8824686

Group type: EXPERIMENTAL
Intervention: Capsaicin (1% in 50% ethanol) applied for 7 days on one forearm
Number of subjects: 13

Group type: COMPARATOR
Intervention: Capsaicin vehicle applied on the contralateral forearm
Number of subjects: 13
Study: 1597024

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 4061000

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with aspiration of 3 ml of CSF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spinal anaesthesia without aspiration of CSF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with a mixture of 3 ml of aspirated CSF and 3 ml of 0.5% isobaric bupivacaine
Number of subjects: 60
Study: 30789848

Group type: EXPERIMENTAL
Intervention: PD-L1 testing by immunohistochemistry (IHC) using unstained slides with TMA tissue cores from NSCLC and tonsil tissues.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Fit-for-purpose PD-L1 assay
Number of subjects: 104
Study: 28933314

Group type: EXPERIMENTAL
Intervention: Low support, remotely accessible, computerized working memory training programme
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MRI scanning
Number of subjects: 90
Study: 27020830

Group type: EXPERIMENTAL
Intervention: High-energetic focused ESWT (0.3 mJ/mm2, 4 Hz, 1000 impulses, 10 J)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Repetitive high-energetic focused ESWT (3 sessions of 0.3 mJ/mm2, 4 Hz, 3 × 1000 impulses, totaling 30 J)
Number of subjects: 26
Study: 24507404

Group type: EXPERIMENTAL
Intervention: Early coronary artery bypass grafting (CABG)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Standard myocardial protection and routine use of internal mammary artery or other arterial grafts
Number of subjects: 347
Study: 21873358

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg capsules
Number of subjects: 1898

Group type: COMPARATOR
Intervention: Warfarin 5 mg tablets
Number of subjects: 1898
Study: 20807884

Group type: COMPARATOR
Intervention: Fruits and Vegetables (F/V)
Number of subjects: 459

Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 459
Study: 18050196

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16286519

Group type: COMPARATOR
Intervention: Calorie-restricted low-dairy diet (CR) - approximately 1 serving dairy/day, 500 mg calcium/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Calorie-restricted high-dairy diet (CR+D) - 3 to 4 servings dairy/day, 1200 to 1400 mg calcium/day
Number of subjects: 54
Study: 11201422

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Aim-directed therapy
Number of subjects: 56
Study: 9517760

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid supplementation per week
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 27.5 mg folic acid supplementation per week
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 8123851

Group type: EXPERIMENTAL
Intervention: ras-positive patients
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ras mutations
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: lower bone marrow blast counts
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: better cytogenetic category
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: aberrant ras allele
Number of subjects: 99
Study: 2955205

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (2 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oestradiol/medroxyprogesterone acetate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oestradiol/levonorgestrel (LNG)
Number of subjects: 18
Study: 30572473

Group type: EXPERIMENTAL
Intervention: Nerve electrical stimulation (NES)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sham NES
Number of subjects: 124